Scalper1 News
Biotech Tetraphase Pharmaceuticals (TTPH) jumped 16% to a new high Thursday and got a volley of price target increases after it reported positive trial results for its antibiotic late Wednesday. The trial found Tetraphase’s eravacycline to be “noninferior” to Merck’s (MRK) Invanz in treating complicated intra-abdominal infections, though the exact number will be reported at a scientific meeting next year. While noninferiority to an existing drug Scalper1 News
Scalper1 News